Drug Profile


Alternative Names: ALN-HBV

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 03 Nov 2017 Alnylam Pharmaceuticals terminates a phase I/II trial in Hepatitis B in United Kingdom (SC) (NCT02826018)
  • 19 Oct 2017 Discontinued - Phase-I/II for Hepatitis B in United Kingdom (SC)
  • 19 Oct 2017 Discontinued - Preclinical for Hepatitis B in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top